Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 + midostaurin
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
CPX-351 + midostaurin is an investigational combination therapy for acute myeloid leukemia (AML) with FLT3 mutations. CPX-351 is a dual-drug liposomal formulation encapsulating daunorubicin and cytarabine in a synergistic 1:5 molar ratio, optimizing interaction between these classic anticancer agents. Midostaurin is a small-molecule oral inhibitor targeting FLT3 (FMS-like tyrosine kinase 3) and additional kinases, intended to block leukemogenic signaling in FLT3-mutated AML. This combination is under clinical investigation (not approved as a combination regimen) primarily for newly diagnosed AML with FLT3 mutations, where preclinical and early clinical trials (e.g., V-FAST) suggest a feasible safety profile and promising remission rates[1][3].
- Brand names
- VyxeosRydapt
- Other names
- Vyxeos liposomaldaunorubicin + cytarabine liposomePKC412PKC-412PKC 412
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)DNA polymerase familyTOP2A (DNA topoisomerase II)PDGFR (PDGFR family)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNA
Beyond the preview
Go deeper on CPX-351 + midostaurin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 + midostaurin.